Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Inborn infants at term gestation (38-42 weeks)~* Apgar score ≤ 3 at 5 minutes and/or delayed first breath beyond five minutes after birth~* Profound metabolic or mixed acidosis with serum bicarbonate \<12 mMol/L in initial arterial blood gas~* Evidence of encephalopathy such as stupor, coma, seizures, or hypotonia in the immediate neonatal period~Exclusion Criteria:~* Twin gestation~* Maternal diabetes~* Congenital malformations of the central nervous system~* Chromosomal abnormalities~* Chorioamnionitis and congenital infections~* Intrauterine growth restriction

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- EPO HIE Group (Type: EXPERIMENTAL): Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
- Control HIE (Type: NO_INTERVENTION): Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
- Healthy Controls (Type: OTHER): Healthy newborn without hypoxic ischemic encephalopathy

Based on this trial design, predict the completion outcome and termination type (if applicable).